Pharmaceutical Rsrch & Mfrs of America
Pharmaceutical Research and Manufacturers of America (PhRMA), founded in 1958, is a trade group representing the pharmaceutical research and biotechnology companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies. PhRMA's current CEO is John J. Castellani.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2010 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q3 2013. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Bundled ContributionsMoney raised by the firm from multiple donors on behalf of the recipient. The firm's own contributions are not included.
Recipient Lobbyist Amount National Republican Senatorial Cmte Jennifer A. Swenson $32,500
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Pharmaceutical Rsrch & Mfrs of America
Names of Lobbyists
Firm Hired Amount Pharmaceutical Rsrch & Mfrs of America $47,890,520
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Economics & Econ Development,
- Science & Technology
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1548 Pathway for Biosimilars Act H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R.3200 America's Affordable Health Choices Act of 2009 S.515 Patent Reform Act of 2009 H.R.1260 Patent Reform Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.4872 Health Care and Education Affordability Reconciliation Act of 2010 S.726 Promoting Innovation and Access to Life-Saving Medicine Act S.369 Preserve Access to Affordable Generics Act
RegulationsMentioned in 121 dockets; Submitted to 45 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Pharmaceutical Rsrch & Mfrs of America" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Pharmaceutical Rsrch & Mfrs of America
- Toggle 3 USTR 2009 Special 301 2009
- Toggle 3 FDA Draft Guidance for Industry and Investigators on Safety Reporting Requirements for INDs and BA/BE Studies; Availability 2010
- Toggle 2 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Format Variations in the Brief Summary of Direct-to-Consumer (DTC) Print Advertisements. 2010
- Toggle 1 FDA Investigational New Drug Applications; Co-Development of Investigational Drugs 2010
- Toggle 1 FDA Draft Guidance for Industry on Non-Inferiority Clinical Trials; Availability 2010
- Toggle 1 FDA Draft Guidance for Industry on Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment; Availability 2010
- Toggle 1 FDA Draft Guidance for Industry on Good Importer Practices; Availability 2009
- Toggle 1 FDA Developing Guidance on Naming, Labeling, and Packaging Practices to Reduce Medication Errors; Public Workshop, Request for Comments 2010
- Toggle 1 HHS Group Health Plans and Health Insurance Coverage: Interim Final Rules for Relating to Status as a Grandfathered Health Plan under the Patient Protection and Affordable Care Act 2010
- Toggle 1 HHS Request for Information on Development of an Inventory of Comparative Effectiveness Research 2010
Mentions in Document Text
View all mentions data for Pharmaceutical Rsrch & Mfrs of America
- Toggle 18 USTR 2010 Special 301 2010
- Toggle 12 USTR Special 301 FR notice 2010
- Toggle 10 FDA Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner 2009
- Toggle 10 FDA Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing 2009
- Toggle 9 FDA FDA Transparency Task Force; Public Meeting 2009
- Toggle 9 USTR 2009 Special 301 2009
- Toggle 7 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 5 CMS Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2005 2010
- Toggle 5 CMS Medicare Program; Medicare Coverage Gap Discount Program Model Manufacturer Agreement and Announcement of the June 1, 2010 Public Meeting 2010
- Toggle 5 FDA Public Workshop: ICH S2 Genetic Toxicology Issues 2009
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Pharmaceutical Rsrch & Mfrs of America" that sat on federal advisory committees.
- Toggle Department of Commerce 1 person on 1 committee